Leukocytospermia does not negatively impact outcomes in in vitro fertilization cycles with intracytoplasmic sperm injection and preimplantation genetic testing for aneuploidy: findings from 5435 cycles
Journal of Assisted Reproduction and Genetics · 2024
DOI: 10.1007/s10815-024-03085-x ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Assisted Reproduction and Genetics, 2024. Verfasst von Pavan Gill und 6 weiteren Autor:innen. Beteiligte Einrichtung: IVI-RMA New Jersey, Basking Ridge, NJ, USA. pgill@ivirma.com. Hauptthemen laut MEDLINE: Sperm Injections, Intracytoplasmic, Aneuploidy, Preimplantation Diagnosis, Fertilization in Vitro. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
To investigate whether leukocytospermia (defined as the presence of ≥ 1 × 10 6 white blood cells/mL) affects clinical and embryologic outcomes in in vitro fertilization (IVF) cycles with intracytoplasmic sperm injection (ICSI) and preimplantation genetic testing for aneuploidy (PGT-A).
Methods
This was a retrospective cohort study including 5425 cycles between January 2012 to December 2021 at a single large university-affiliated fertility clinic. The primary outcome was live birth rate (LBR).
Results
The prevalence of leukocytospermia was 33.9% ( n = 1843). Baseline characteristics including female age, BMI, AMH, Day 3 FSH, and male partner’s age were similar in cycles with and without leukocytospermia. The LBR after the first euploid embryo transfer was similar in those with and without leukocytospermia (62.3% vs. 63% p = 0.625). Secondary outcomes including clinical pregnancy rate (CPR), sustained implantation rate (SIR), fertilization (2PN) rate, blastulation rate, and aneuploidy rate were also evaluated. The CPR (73.3% vs 74.9%, p = 0.213) and SIR (64.6% vs. 66%, p = 0.305) were similar in both groups. The 2PN rate was also similar in both groups (85.7% vs. 85.8%, p = 0.791), as was the blastulation rate per 2PN (56.7% vs. 57.5%, p = 0.116). The aneuploidy rate was not significantly different between groups (25.7% vs 24.4%, p = 0.053). A generalized estimation equation with logistic regression demonstrated that the presence leukocytospermia did not influence the LBR (adjusted OR 0.878; 95% CI, 0.680–1.138).
Conclusion
Leukocytospermia diagnosed just prior to an IVF cycle with PGT-A does not negatively impact clinical or embryologic outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- IVI-RMA New Jersey, Basking Ridge, NJ, USA. pgill@ivirma.com.
- IVI Foundation, Valencia, Spain.
- IVI-RMA New Jersey, Basking Ridge, NJ, USA.
- School of Medicine Andrology and IVF Laboratories, University of Utah, Salt Lake City, UT, USA.
Zitieren
APA
Gill, P., Puchalt, N. G., Molinaro, T., Werner, M., Seli, E., Hotaling, J., & Cheng, P. (2024). Leukocytospermia does not negatively impact outcomes in in vitro fertilization cycles with intracytoplasmic sperm injection and preimplantation genetic testing for aneuploidy: findings from 5435 cycles. Journal of Assisted Reproduction and Genetics. https://doi.org/10.1007/s10815-024-03085-x
Vancouver
Gill P, Puchalt NG, Molinaro T, Werner M, Seli E, Hotaling J, et al. Leukocytospermia does not negatively impact outcomes in in vitro fertilization cycles with intracytoplasmic sperm injection and preimplantation genetic testing for aneuploidy: findings from 5435 cycles. Journal of Assisted Reproduction and Genetics. 2024. doi:10.1007/s10815-024-03085-x
BibTeX
@article{Gill2024,
author = {Gill, Pavan and Puchalt, Nicolas Garrido and Molinaro, Thomas and Werner, Marie and Seli, Emre and Hotaling, James and Cheng, Philip},
title = {Leukocytospermia does not negatively impact outcomes in in vitro fertilization cycles with intracytoplasmic sperm injection and preimplantation genetic testing for aneuploidy: findings from 5435 cycles},
journal = {Journal of Assisted Reproduction and Genetics},
year = {2024},
doi = {10.1007/s10815-024-03085-x}
}
EUVIMED